Post transplant infusion of donor-type natural killer (NK) cells has been shown to have an anti-leukemia-enhancing effect without evoking GVHD in murine hematopoietic cell transplantation (HCT) models. Here, we tested 14 patients (age, 23-65 years), 12 with acute leukemia and 2 with myelodysplastic syndrome, who underwent HLAmismatched HCT and subsequently received donor NK cell infusions. Cell donors (age, 16-51 years), comprising seven siblings, five offspring, and two mothers of the patients, underwent growth factor-mobilized leukapheresis for 3-5 days. Cells collected on the first 2-4 days were used for HCT, whereas those collected on the last day were CD34 selected by magnetic-activated cell sorting (median, 2.22 Â 10 6 cells/kg; range, 0.29-5.66). Donor NK cells were generated from the CD34 þ cells by ex vivo cell culture over a 6-week period (median, 9.28 Â 10 6 cells/ kg; range, 0.33-24.50; CD122/CD56 þ 64%; CD3 þ 1.0%; and viability 88%). There were no signs of acute toxicity in patients infused with these cells 6-7 weeks post transplant. Overall, one and five patients developed acute and chronic GVHD during post transplant period, respectively. These results showed that clinical-grade donor NK cell production from CD34 þ cells is feasible.
Introduction
Natural killer (NK) cells, originally described based on their ability to kill target cells in vitro without prior sensitization of their host, 1,2 constitute a unique subset of lymphocytes that is involved in the innate immunity against malignancies and infections. Unlike their T-cell counterparts, NK cells express CD56, but not CD3, and can kill tumor cells without restriction by MHC molecules expressed on the target. 3, 4 In fact, NK cell activation is enhanced by the absence or a change in the expression of MHC class I antigen on tumor cells because of a failure to engage inhibitory receptors, notably killer immunoglobulin-like receptors (KIR), on NK cells. 5, 6 This diminished inhibitory influence combined with stimulation of activating receptors, notably NKG2D, by tumor ligands 7 produces a cumulative effect on NK cell activation that leads to subsequent tumor cell killing. In murine allogeneic hematopoietic cell transplantation (HCT) models, NK cells of donor origin exhibit enhanced anti-tumor effects without increasing GVHD when given after HCT. 8, 9 It has been postulated that the normal host tissues lack an activating ligand, and thus avoid donor NK cell-mediated tissue damage, even in the setting of MHC-mismatched HCT setting. 10, 11 Allogeneic HCT is a well-established curative treatment for a significant proportion of patients with hematologic malignancies and bone marrow failure syndrome. Traditionally, allogeneic HCT has been performed using related-or unrelated-donors who carry HLA that are matched to those of patients. 12 Increasingly, allogeneic HCT from a familymember donor with a fully mismatched HLA haplotype (HLA-mismatched or haploidentical HCT) is being performed using innovative transplantation approaches, [13] [14] [15] [16] including the use of reduced-intensity conditioning. [17] [18] [19] [20] The recurrence of underlying malignant disorders after HCT, however, remains the most frequent cause of treatment failure. Additional infusion of donor lymphocytes after transplantation, which may be effective in preventing or treating recurrence of the underlying malignancy, can cause significant and often fatal GVHD, especially after HLA-mismatched HCT. 21, 22 The ability of NK cells to kill tumor cells without causing GVHD, one of the unique biologic characteristics of NK cells described above, suggests that post transplant infusion of donor NK cells, as opposed to donor lymphocytes, might be an effective treatment approach after HLAmismatched HCT. 23 Several clinical trials have evaluated the feasibility of adoptive transfer of NK cells from an HLA-haploidentical donor into patients with malignancies after HLA mismatched HCT, 24, 25 during autologous HCT, 26 or without prior HCT. 27 In these studies, donor NK cells were obtained from peripheral blood leukapheresis products using a magnetic-activated cell sorting (MACS) system. Up to 9 Â 10 7 HLA-mismatched donor NK cells/kg were given without causing GVHD. 26 The maximum number of donor NK cells that can be given to patients after HLA-mismatched HCT without causing serious GVHD as well as any potential clinical benefit obtainable by such treatment remain to be defined. In addition to acquiring donor NK cells from peripheral blood leukapheresis products by MACS, donor NK cells can be generated by differentiation from CD34 þ progenitor cells. [28] [29] [30] In this study, we examined the feasibility of generating clinical-grade donor NK cells from CD34 þ progenitor cells collected from donors through leukapheresis after mobilization. We then evaluated the side effects (including GVHD) of infusion of donor NK cells thus obtained after HLA-mismatched HCT.
Patients and methods
Patients, HLA-mismatched HCT, and post-transplant donor NK cell infusion A protocol for donor NK cell infusion after HLAmismatched allogeneic HCT was initiated in May 2007, and 18 patients were enrolled by October 2008. The treatment paradigm is outlined in Figure 1 . All participating patients had advanced acute leukemia or myelodysplastic syndrome and were unable to find suitable HLA-matched donors in their family or from donor registries. HLA-A, -B, -C, and -DR typing of the patients and donors was performed using PCR sequencing-based methods or by serologic methods. The procedure for HLA-mismatched HCT has been described elsewhere. 20 Briefly, the conditioning regimen included busulfan 3.2 mg/kg/day i.v. on days À7 and À6 of HCT (where day 0 is the first day of donor hematopoietic cell infusion), fludarabine 30 mg/m 2 /day i.v. on days À7 to À2, and thymoglobulin (Genzyme Transplant, Cambridge, MA, USA) 3 mg/kg/day i.v. on days À4 to À1. Starting on day À3, each hematopoietic cell donor was given G-CSF 10 mg/kg subcutaneously daily for 5-7 days. Starting on the fourth day of G-CSF administration (day 0 of HCT), donor mononuclear cells were collected daily by large-volume leukapheresis (CS3000, Baxter, Deerfield, IL, USA) for 3-5 days. The goal was to collect at least 5 Â 10 6 CD34 þ cells/kg for HCT. The cells collected during the first 2-4 days were administered to patients through central venous catheters on the same days. The cells collected on the last day were transported to the laboratory for the generation of donor NK cells (see below). For GVHD prophylaxis, cyclosporine and a short course of methotrexate were given after HLA-mismatched HCT.
Of 18 patients who enrolled in the study, 4 were unable to receive donor NK cells because of expansion failure/cell culture contamination (n ¼ 2), CD3-positive cells 410% in the final cell culture product (n ¼ 1), or early death because of rapidly progressing ALL (n ¼ 1). Fourteen patients Cell infusion into the patient Figure 1 Outline of treatment paradigm for donor NK cell infusion after HLA-mismatched allogeneic HCT. Patients in the study received conditioning therapy for HCT with busulfan, fludarabine, and anti-thymocyte globulin between days À7 and À1. Cyclosporine and a short course of methotrexate were given for GVHD prophylaxis. Hematopoietic cell donors received G-CSF starting on day À3 and underwent large-volume leukapheresis for 3-5 days (depending on the number of CD34 þ cells collected during the first 2 days) beginning on day 0. The goal was to transplant 45 Â 10 6 CD34 þ cells/kg. Mononuclear cells collected on the first 2-4 days were transplanted into the patients on the same days. Cells collected on the last day were transported to the laboratory, where they were separated into CD34 þ cells, then differentiated in vitro into NK cells. Donor NK cells thus generated were infused into patients approximately 6-7 weeks after HLA-mismatched allogeneic HCT.
(8 male and 6 female; median age: 39.5 years, range, 23-65; summarized in Table 1 ) received donor NK cell infusions between 43 and 50 days after HLA-mismatched HCT, as per the protocol. At the time of donor NK cell infusion, all patients met the following criteria: a Karnofsky Performance Scale X70, no acute GVHD4grade 1, no active infection, and adequate organ function (total bilirubin o3.0 mg/100 ml, aspartate aminotransferase o250 U/l, creatinine o2.0 mg/100 ml, and no clinically evident cardiac dysfunction). The protocol was approved by the Asan Medical Center Institutional Review Board and the Korean Food and Drug Administration (KFDA), and is listed on the National Cancer Institute (Bethesda, MD, USA) clinical trial registry at www.cancer.gov as #NCT00569283. All patients and donors participating in the study provided informed written consent. Donor NK cells were infused into patients over 1 h through a central venous catheter. Half an hour before NK cell infusion, pheniramine 45.5 mg was administered by brief i.v. infusion. The first patient in the study received donor NK cell infusion in the hospital, but all 13 subsequent patients received infusions in the outpatient clinic.
Patient evaluations
The first days on which ANC over 500/ml for 2 consecutive days and the first days of unsupported platelet counts over 20 000/ml for 7 consecutive days were recorded for neutrophil and platelet engraftments, respectively. Acute and chronic GVHD were diagnosed and graded according to published criteria. 31, 32 A PCR-based procedure using short tandem DNA repeats was used to analyze hematopoietic chimerism 2, 4, 6, 8, 12, and 24 weeks after HCT. On the day of donor NK cell infusion, all patients were observed for at least 4 h for any acute toxicity. Subsequently, patients were evaluated at least weekly for 4 weeks, then as necessary for at least 3 months by physical examination and laboratory testing, which included complete blood counts and chemistry profile. Toxicities were graded according to the Common Terminology Criteria for Adverse Events, v3.0 (National Cancer Institute, Bethesda, MD, USA).
Donor NK cell generation
Donor NK cells were generated in a KFDA-inspected laboratory located in the hospital. CD34 þ progenitor cells were separated from the leukapheresis product on a CliniMACS system (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) using anti-human CD34 microbeads. CD34 þ cells were then cultured in T-75 flasks containing Myelocult complete media (Stemcell Technologies, Vancouver, BC) containing human stem cell factor (30 ng/ml, PeproTech, Rocky Hill, NJ, USA), human fms-related tyrosine kinase 3 (Flt3) ligand (50 ng/ml, PeproTech), human IL-7 (5 ng/ml, PeproTech), and hydrocortisone (10 -6 M, Stemcell Technologies) in 5% CO 2 at 37 1C. The cells were cultured at a density of 2 Â 10 6 cells/ml. When the cell count reached around 4 Â 10 6 cells/ml, half the media was replaced with fresh complete media containing same cytokines. After 21 days, cells were collected, washed, and transferred to Myelocult complete media containing human IL-15 (30 ng/ml, PeproTech), human IL-21 (30 ng/ml, PeproTech), and hydrocortisone (10 -6 M). Half the media was replaced with fresh complete media weekly. After 21 days, cells were collected, washed extensively, and suspended in 50 ml human albumin solution (5%) and infused into patients. The cytokines used in the donor NK cell generation were of research grade.
Immunophenotyping Leukapheresis and NK cell products were immunophenotyped by flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA) after fluorescence labeling with antihuman CD3, CD34, CD122, CD56, CD16, CD94, NKG2D, NKp46, and KIR antibodies (KIR2DL1, KIR2DL3, and KIR3DL1). The purity of the cells was calculated as CD3 Cr (PerkinElmer, Waltham, MA, USA) and plated in 96-well plates. Donor NK cells were added to the plates at 10:1, 5:1, and 2.5:1 effector: target ratios. After 4 h incubation, the supernatants were collected and radioactivity was measured using a g counter (PerkinElmer). Results are expressed as the percent-specific release based on the formula, percent-specific lysis ¼ (experimental releaseÀspontaneous release) Â 100/ (maximal releaseÀspontaneous release). Granzyme and perforin gene expressions in donor NK cells were detected by RT-PCR. Cytokine-secreting ability of donor NK cells was determined by measuring IFN-g and TNF-a in the culture supernatant by ELISA using human IFN-g and TNF-a ELISA Development kits (RandD System, Minneapolis, MN, USA).
Quality control
To ensure the quality of donor NK cell products, the following tests were performed: culture supernatants were tested for bacteria and optical density was measured; RT-PCR was used to test for mycoplasma and virus (hepatitis viruses B and C, CMV, EBV, HIV, and human T-lymphotrophic virus); and a Limulus-Amebocyte-Lysate test was used to measure endotoxin. The final NK cell products from all 14 donors in the study showed no bacterial growth and no increase in optical density compared with control culture media, negative RT-PCR results for mycoplasma and all the viruses tested, and an endotoxin contents o0.5 EU/ml.
Comparison of fresh versus cultured donor NK cells and the survival of cultured donor NK cell in nude mouse
In a separate experiment, we obtained NK cells from a mobilized leukapheresis product from a healthy donor (45-years-old female) by MACS (CD3 þ depletion then The number of HLA disparities between the patient and donor is based on a consideration of the six antigens of HLA-A, -B, and -DR. 
Results

Characteristics of the patients and donors
The demographic characteristics of the 14 patients and their donors are summarized in Table 1 . Clinical data for 8 of 14 patients have been described elsewhere. 20 Eleven patients in this study had AML, one had ALL, and two had myelodysplastic syndrome. At the time of HCT, of the 12 patients with acute leukemia, 1 was in the first CR after salvage chemotherapy, 5 were in second or subsequent CR, and 6 exhibited refractory disease. Hematopoietic cell donors (median age, 35 years; range, 16-51) were siblings (n ¼ 7), offspring (n ¼ 5), or mothers (n ¼ 2) of the patients. In 13 patient-donor pairs, there were two to three disparities of the six HLA-A, -B, and -DR antigens, either in the GVH or rejection directions. One patient-donor pair had a single antigen disparity for both the GVH and rejection directions. In this pair, however, PCR-based typing revealed three disparities among eight HLA-A, -B, -C, and -DR antigens in both directions. When classified according to KIR ligand incompatibility, 33 four of our patient-donor pairs exhibited NK cell alloreactivity (UPNs 558, 568, 630, and 661; Table 1 ), and eight pairs did not. In two pairs (UPNs 549 and 551), NK cell alloreactivity could not be determined because of a lack of molecular HLA data.
Twelve cell donors in the study underwent three daily leukapheresis procedures, whereas two donors required four (UPN 618 donor) or five (UPN 590 donor) because of low CD34 þ cell numbers. For HCT, a median of 8. 
Clinical courses
The clinical courses of patients after HCT from an HLAmismatched familial donor are summarized in Table 2 . All patients experienced primary engraftment of donor cells with an ANC4500/ml between 11 and 23 days after HCT and a platelet count420 000/ml between 13 and 30 days after HCT. Doses of prophylactic cyclosporine were tapered beginning 27-61 days after HCT. One patient developed grade 2 acute GVHD involving the skin 51 days after HCT. Four patients developed chronic GVHD between 58 and 111 days after HCT (two mild, one moderate, and one severe). Of six patients with refractory acute leukemia at the time of HCT, four achieved CR after HCT but three relapsed. Two patients failed to achieve CR after HCT and both received donor NK cells during active leukemia (UPNs 592 and 648). Of six patients with acute leukemia in CR status at HCT, four relapsed. The two myelodysplastic syndrome patients were surviving in CR status with good marrow function for 21.6 and 16.2 months after HCT, respectively.
Donor NK cells generated from CD34
þ progenitor cells The numbers of mononuclear and CD34 þ cells obtained from each donor, as well as the numbers and characteristics of NK cells generated from CD34 þ cells are presented in Table 3 . The mean number of mononuclear cells collected from donors for NK cell generation was 3.49 Â 10 8 /kg body weight of the recipients (range, 1.8-6.3 Â 10 Immunophenotyping of mature NK cells showed that the mean CD122/CD56-double-positive rate was 64% (range, 36-90%), and the mean CD3-positive rate was 1.0% (range, 0-2.6%). Mean viability as measured by propidium iodide staining and FACS analysis was 88% (range, 73-96%). RT-PCR analyses showed that mature NK cells derived from all 14 donors expressed the granzyme gene, and NK cells from 11 donors also showed perforin gene expression. A 51 Cr-release assay using K562 cells as target cells demonstrated that all donor NK cells possessed cytotoxic activity, which increased at higher effector-target ratios. Analyses of NK cell receptor expression in a limited number of samples revealed the following: mean CD94 expression, 60% (n ¼ 6); mean KIR2DL1 expression, 1.9% (n ¼ 4); mean KIR2DL3 expression, 4.6% (n ¼ 5); mean KIR3DL1 expression, 3.0% (n ¼ 4); mean NKG2D expression, 70.3% (n ¼ 3); and mean NKp46 expression, 62.3% (n ¼ 3). In the final cell culture supernatant, the mean concentrations of INF-g and TNF-a were 53 pg/ml (range, 0-184) and 144 pg/ml (range, 26-548), respectively.
Fresh versus cultured donor NK cells
When compared with the fresh donor NK cells, the cultured donor NK cells showed lower expression of inhibitory receptors (KIR2DL1, KIR2DL2/3, and KIR3DL1), whereas showing higher expression of activating receptors (NKp30, NKp44, and NKp46; Supplementary The patient was found dead at home. During a routine follow-up visit 4 weeks before her death, she showed no remarkable physical or laboratory findings.
d
After recurrence, salvage chemotherapy with cytarabine and daunorubicin was given and the patient achieved CR4. Unfortunately, the patient died subsequently because of uncontrolled hemoptysis.
e
The recurrence was confined to the chest with malignant pleural effusion. Leukemia persisted despite initial prophylactic cyclosporine discontinuation and subsequent two cycles of combination chemotherapy with fludarabine and cytarabine.
f After recurrence, salvage chemotherapy with cytarabine, mitoxantrone, and etoposide was given. The patient subsequently underwent a second HLA-mismatched HCT (son). Unfortunately, the patient experienced leukemia recurrence 4 months later.
g
The patient showed persistent leukemia (15%) in a bone marrow examination on day 35 with increasing leukemic blast in the peripheral blood . Prophylactic cyclosporine was discontinued on day 38 and donor NK cells (4.5
/kg) were infused on day 44. Despite the treatment, the white blood cell count continued to increase and the patient died because of central nervous system hemorrhage 9 days later.
h After recurrence, prophylactic cyclosporine was discontinued. The patient died shortly thereafter with an increased white blood cell count and respiratory failure.
i After recurrence, prophylactic cyclosporine was discontinued. Owing to lack of response, salvage chemotherapy with fludarabine and cytarabine was given. The patient died 3 months later because of progressive leukemia. The patient showed persistent leukemia (29%) in a bone marrow examination conducted on day 37. Prophylactic cyclosporine was discontinued on day 44 and, on the same day, donor NK cells (12.1
were infused. Despite the treatment, the patient showed increasing blasts in the peripheral blood on day 71. Subsequently, salvage chemotherapy with cyclophosphamide, doxorubicin, vincristine, methylprednisolone was given without subsequent remission. Figure S3) . However, IFN-g and TNF-a secretion was higher in the cultured NK cells (Supplementary Table S1 ). When injected into nude mice, the cultured donor NK cells were detectable by flow cytometry using anti-human CD56 up to 14 days (Supplementary Figure S4) .
Untoward effects of donor NK cell infusion
The median follow-up period of surviving patients after donor NK cell infusion was 18.7 months (range, 14.7-24.4 months). All 14 patients in the study tolerated donor NK cell infusion well without any acute side effects, such as fever, headache, nausea/vomiting, or hypotension. In weekly or biweekly monitoring of patients up to 3 months after donor NK cell infusion, two patients showed transient, grade 3 elevation of alanine aminotransferase, but the relationship between this elevation and donor NK cell infusion was not certain. One patient (UPN 648, Table 2 ) developed grade 2 skin GVHD 7 days after donor NK cell infusion. However, prophylactic cyclosporine had been discontinued in this patient at the time of donor NK cell infusion because of persistent leukemia evident on post transplant bone marrow examination. Thus, a causative relation between donor NK cell infusion and acute GVHD was not clearly established in this case. None of the other 13 patients developed acute GVHD after donor NK cell infusion. As described above, four patients developed chronic GVHD 14-68 days after the donor NK cell infusion. However, it could not be ascertained whether chronic GVHD in these patients was due to HLAmismatched HCT itself or to donor NK cell infusion. Donor NK cell infusion did not produce an anti-leukemia effect in either of two patients (UPNs 592 and 648) who had active leukemia after HCT at the time of donor NK cell infusion.
Discussion
Traditionally, HLA-mismatched HCT has been considered ill advised in a routine clinical practice setting because of excessive serious post transplant complications, such as graft failure, GVHD, and prolonged immunosuppression with increased susceptibility to infections. 12 However, the recent introduction of new HCT techniques, especially in the area of conditioning therapy, has improved outcomes after HLA-mismatched HCT.
14,17-20 Our strategy for HLAmismatched HCT without ex-vivo T-cell depletion-specifically, using conditioning therapy with busulfan in reduced dose, fludarabine, and anti-thymocyte globulin-showed that HLA-mismatched HCT is feasible with consistent donor cell engraftment and without excessive GVHD, as well as without excessive transplantation-related mortality. 20 HLA-mismatched HCT using NK cell biology may provide a unique opportunity to control underlying malignancies after HCT. NK cells derived from the same donor as used for HLA-mismatched HCT, when infused after HCT, would not be rejected by the patient and might provide a more consistent anti-tumor effect without causing significant GVHD. 8, 10, 23 Clinically, NK cells from the hematopoietic cell donor can be obtained using one of the two main methods. The first is separation of NK cells from the leukapheresis product using a MACS system. [24] [25] [26] [27] From a single-day leukapheresis product, about 1-2 Â 10 7 ) with an average CD122/CD56-double-positive rate of 63% (range, 36-90%). Although a limited number of cases were analyzed, these cells expressed activating NK cell receptors, including NKG2D and NKp46, and showed in vitro cell cytotoxicity against K562 cells. CD3 expression was minimal (mean, 1.0%).
In an experiment involving a single hematopoietic cell donor, the NK cells differentiated from CD34 þ cells showed different pattern of receptor expression, cell cytotoxicity, and cytokine secretion, when compared with the NK cells obtained by MACS separation. The donor NK cells differentiated from CD34 þ cells survived in nude mice for 2 weeks. In the future, it may become possible to modulate donor NK cell receptor repertoire, as well as cell cytotoxicity, for optimum cell therapy.
Infusion of donor NK cells obtained in our study into patients 6-7 weeks after HLA-mismatched HCT caused no acute side effect. In all, one and four patients developed acute and chronic GVHD, respectively, in our case series. However, it cannot be ascertained whether GVHD in these patients were due to HLA-mismatched HCT itself or because of subsequent donor NK cell infusion. At the time of donor NK cell infusion, two patients in our study had active leukemia. In neither case was there an anti-leukemia effect of donor NK cell infusion. Future clinical studies will be required to determine the potential effects of antithymocyte globulin, an immunosuppressive agent known to have a prolonged half-life in the blood, 34 and prophylactic cyclosporine 35 on the biologic functions of infused donor NK cells.
Taken together with the general absence of literature reports of significant side effects, including GVHD, associated with infusion of up to 1-2 Â 10 7 donor NK cells/kg, 24, 25, 27 the results of our current study suggest that further clinical studies on the effects of higher doses of donor NK cells are warranted. A number of approaches might be considered to increase the yield of NK cells, including increasing the number of leukapheresis procedures, combining NK cells obtained by MACS separation and differentiation from the donor progenitor cells, and developing better methods to induce NK cell differentiation from donor progenitor cells. In addition to defining the maximum dose of donor NK cells that can be given after HLA-mismatched HCT without causing serious side effects or GVHD, possible anti-leukemia effects of donor NK cell infusion should also be investigated.
In conclusion, our study showed that clinical-grade NK cells could be generated from donor CD34 þ cells collected through leukapheresis after mobilization with G-CSF. The average number of donor NK cells generated from 1-day leukapheresis product was 9.28 Â 10 6 /kg. When given 6-7 weeks after HLA-mismatched HCT, these cells were well tolerated by patients. Further research is planned to increase the number of clinically obtainable donor NK cells and to investigate the maximum number of donor NK cells that can be given without causing serious side effects.
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